In Vitro Diagnostics Business Outlook: Volume 1, Issue 14 - Point-of-Care (POC) COVID-19 Testing
9 May 2022
Categories:
In Vitro Diagnostics Business Outlook
A new twice-monthly publication dedicated to IVD, In Vitro Diagnostics Business Outlook offers the following:
• Market Sizing and Forecasting of IVD Market Segments in Every Issue
• Clinical Chemistry, Infectious Disease Testing, Oncology, Hematology, Blood Banking, Coagulation, Point of Care–Updates on the Important Test Categories You Need to Know About
• Industry Watch – Developments with COVID-19 and Other Testing
• M&A, Distribution, Partnerships Tracked and Charted
• New Product Introductions and Company Announcements
• Company Profiling and Quarterly Results Summaries
• Regional Market Coverage
Table of Contents
-
Market Analysis: POC COVID-19 Testing
- Overview of POC COVID-19 Testing
-
Market Outlook
- Major Product Activity
- Setting Market
-
Top Company Briefs
- Abbott
- Roche
- Quidel
- Becton Dickinson
-
Executive News Briefing
- Pathware Appoints New CEO
- Mainz Biomed Appoints New COO
- Personalis Appoints New VP of Diagnostic Sales
-
Financial Highlights: bioMérieux, Guardant Health, Lucira Health
- bioMérieux Full-Year Sales up 10.5% in 2021 Like-for-Like
- Guardant Reports Growth in Clinical (+38.5%) and Biopharma (+16.5%) Test Volumes
- Lucira Health Reports First Full Year of Commercialization
-
Diagnostic Market Mergers, Acquisitions and Partnership Deals
- Partnerships and Collaborations
- Mergers and Acquisitions
-
Industry Watch
- COVID-19 Update
-
Region Watch
- Kenya
- Saudi Arabia
-
Broad-based Company Announcements
- Biomerica Submitted H. pylori Test to FDA
- Bruker Launches New LiquidArray Multiplex PCR Assays
- C2i Genomics Launched MRD Test in Europe